期刊文献+

罗氏e601型电化学发光分析仪测定癌胚抗原的方法学性能评价 被引量:4

Methodology performance of Roche e601 electrochemical illuminescent analyzer for determining carcinoembryonic antigen
下载PDF
导出
摘要 目的通过对罗氏e601型电化学发光分析仪测定癌胚抗原的方法学性能评价,探讨临床免疫学定量检测的方法学性能验证评价方案和实验方法。方法按照CLSI推荐的方法测定癌胚抗原的精密度、正确度、线性范围和可报告范围、分析灵敏度(最低检测限)、生物参考区间的验证、携带污染率指标进行验证。结果癌胚抗原的方法学评价结果在厂家提供的范围之内,癌胚抗原的生物参考区间范围不受地区和人群等因素的影响。结论罗氏e601型电化学发光分析仪检测系统性能能满足临床要求,评价方案科学可靠,厂家提供的数据必须经验证后才能引用。 Objective To evaluate the performance methodology of Roche e601 electrochemical illumineseent analyzer for determining eareinoembryonie antigen , and to verify the evaluation program and the experimental method by the performance of methodology of elinleal immunological quantitative detection emthods. Methods According to a method by CLSI ereommended, the precision , aeeuraey,linear range , reportoble range and analytieal ~nsifivity(lowest detectable limit) of eareinocmbryonie antigen were determined. Biological reference interval and carryover indicators were verified. Results The results of the performance of methodology were consistent with accuracy claimed by manufacturers. Biologieal reference interval was not -fleeted by the environment and population. Conclusions The Roche e601 eleetroehemieal illuminescent analyzer can meet the requirements of clinical testing. The evaluation program is seientifie and reliable ; data provided by the manufacturers should be verlfleated first before using.
作者 麦爱芬
出处 《医学检验与临床》 2012年第5期13-15,共3页 Medical Laboratory Science and Clinics
关键词 肿瘤标记物 方法学性能 评价 Tumor markers Methodology Performance Evcluation
  • 相关文献

参考文献9

二级参考文献25

  • 1张莉,吴炯,郭玮,潘柏申.医学检验检测系统应用前的性能评价[J].检验医学,2006,21(6):560-563. 被引量:71
  • 2U. S. Department of Health and Human Services. 42 CFR Part 493: medicare, medicaid and CLIA programs; Laboratory requirements relating to quality systems and certain personnel qualifications; Final rule[J]. Federal Register, 2003,68 : 3640-3714.
  • 3CLSI. EP6-A2,evaluation of the linearity of quantative analytical methods. 2003:1-47.
  • 4CLSI. C28-A2. how to define and determine reference intervals in the clinical laboratory. 2000:1-31.
  • 5U.S. Department of Health and Human Services. 42 CFR Part 493: medicare, medicaid and CLIA programs;Laboratory requirements relating to quality systems and certain personnel qualifications; Final rule[ J ]. Federal Register, 2003,68:3640-3714.
  • 6Jan SK. Evaluation of assay systems [ J ]. Clin Lab News,2001,27 : 10-14.
  • 7Laessig RH, Ehrmeyer SS, Leinweber JE. Intralaboratory performance requirements necessary to pass proficiency testing: CAP-1990 vs CLIA-1967 ( March 14,1990) formats compared [ J ]. Clin Chem, 1992,38 :895-903.
  • 8U.S. Department of Health and Human Services.Medical devices;Current good manufacturing practice(CGMP) final rule :quality system regulation. 21 CFRParts 808,812 and 820 [ J ]. Federal Register, 1996,61 : 52602-52662.
  • 9National Committee for Clinical Laboratory Standards.Evaluation of precision performance of clinical chemistry devices, approved guideline [ S ]. Wayne, PA:EPSoA. NCCLS. 1999.
  • 10U.S. Department of Health and Human Services.Medicare,medicaid and CLIA programs; Regulationsimplementing the clinical laboratory improvement amendments of 1998 (CLIA). Final rule [ J ]. Fed Regist, 1992,57:7002-7186.

共引文献220

同被引文献20

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部